-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, China Resources Sanjiu mentioned in its investor relations activity record sheet that it will raise the price of some OTC produc.
There are two types of OTC products that are expected to increase in price, one is the core variety, and the other is the growing variety under cultivati.
Regarding this price increase, he said that the price increase of core varieties is due to the fact that the price of the core products has not changed for many years, but the cost has risen a lot, so the price of this type of products will be increased gradually, mainly to cover the impact of rising cos.
At the same time, the brand value will be realized, and the patient's acceptance will be fully considered in the process of raising the pri.
The varieties in the growing period are due to the process of gradually increasing the price as the brand power of the product increases; at the same time, after the product experience is continuously upgraded, and the process and packaging design are improved, the price will also be increased according.
According to public information, China Resources Sanjiu has more than 20 varieties of over 100 million, including "999 Ganmaoling", "999 Piyanping", "Sanjiu Weitai", "999 Children's Cold Medicine", "Tianhe Gutong Paste" "Aonuo" has a long-term sales advantage in related categori.
After the price increase, it is expected to play a certain role in improving the revenue of China Resources Sanj.
It is worth noting that this is not the first time that China Resources Sanjiu has disclosed a price increase pl.
On May 9, China Resources Sanjiu accepted an investor survey and said that it will moderately increase the price of some varieties from time to time, such as Ganmaoling in recent yea.
Small price increa.
In addition, in 2021, China Resources Sanjiu also announced that its Angong Niuhuang Pills have raised the pri.
The reason for the price increase is to cover the cost pressure of raw materia.
In fact, in recent years, the news about the price increase of OTC products has been continuo.
For example, as early as 2018, many listed companies, including China Resources Sanjiu and Yunnan Baiyao, introduced in their disclosed investor relations activity records that the company's related products had undergone price increases of varying degre.
Among them, Yunnan Baiyao has raised prices on Band-Aids, hemorrhoid creams and aeroso.
The company said that the price adjustment is mainly considered for channel providers, especially retail termina.
Since March 1, 2018, Foci Pharma has raised prices across the board for more than 100 products in various dosage forms such as concentrated pills, honey pills, water pills, oral liquids, gels, granules, and table.
The ex-factory price has been raised by an average of 16%, and the retail price will also be adjusted according.
In addition, at the end of 2021, Taiji Group also stated on the investor relations interactive platform that the company has recently adjusted the ex-factory price of Huoxiang Zhengqi Oral Liquid, with an average increase of 1
The analysis believes that the price increase of most OTC products is the result of many factors, including the OTC independent pricing model, the continuous increase in the price of upstream Chinese medicinal materials, and the need for downstream retail pharmacies to increase profi.
In general, price increases are basically a common phenomen.
Under the influence of factors such as consistency evaluation, strict inspection and control of production quality by the state, and continuous increase of investment in R&D and sales expenses of products, it is normal for some products to increase in pri.
In the future, the price increase will not be too high, but at the same time as the price increase, the quality promise and service value that the goods can provide to consumers are expected to increase simultaneous.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
There are two types of OTC products that are expected to increase in price, one is the core variety, and the other is the growing variety under cultivati.
Regarding this price increase, he said that the price increase of core varieties is due to the fact that the price of the core products has not changed for many years, but the cost has risen a lot, so the price of this type of products will be increased gradually, mainly to cover the impact of rising cos.
At the same time, the brand value will be realized, and the patient's acceptance will be fully considered in the process of raising the pri.
The varieties in the growing period are due to the process of gradually increasing the price as the brand power of the product increases; at the same time, after the product experience is continuously upgraded, and the process and packaging design are improved, the price will also be increased according.
According to public information, China Resources Sanjiu has more than 20 varieties of over 100 million, including "999 Ganmaoling", "999 Piyanping", "Sanjiu Weitai", "999 Children's Cold Medicine", "Tianhe Gutong Paste" "Aonuo" has a long-term sales advantage in related categori.
After the price increase, it is expected to play a certain role in improving the revenue of China Resources Sanj.
It is worth noting that this is not the first time that China Resources Sanjiu has disclosed a price increase pl.
On May 9, China Resources Sanjiu accepted an investor survey and said that it will moderately increase the price of some varieties from time to time, such as Ganmaoling in recent yea.
Small price increa.
In addition, in 2021, China Resources Sanjiu also announced that its Angong Niuhuang Pills have raised the pri.
The reason for the price increase is to cover the cost pressure of raw materia.
In fact, in recent years, the news about the price increase of OTC products has been continuo.
For example, as early as 2018, many listed companies, including China Resources Sanjiu and Yunnan Baiyao, introduced in their disclosed investor relations activity records that the company's related products had undergone price increases of varying degre.
Among them, Yunnan Baiyao has raised prices on Band-Aids, hemorrhoid creams and aeroso.
The company said that the price adjustment is mainly considered for channel providers, especially retail termina.
Since March 1, 2018, Foci Pharma has raised prices across the board for more than 100 products in various dosage forms such as concentrated pills, honey pills, water pills, oral liquids, gels, granules, and table.
The ex-factory price has been raised by an average of 16%, and the retail price will also be adjusted according.
In addition, at the end of 2021, Taiji Group also stated on the investor relations interactive platform that the company has recently adjusted the ex-factory price of Huoxiang Zhengqi Oral Liquid, with an average increase of 1
The analysis believes that the price increase of most OTC products is the result of many factors, including the OTC independent pricing model, the continuous increase in the price of upstream Chinese medicinal materials, and the need for downstream retail pharmacies to increase profi.
In general, price increases are basically a common phenomen.
Under the influence of factors such as consistency evaluation, strict inspection and control of production quality by the state, and continuous increase of investment in R&D and sales expenses of products, it is normal for some products to increase in pri.
In the future, the price increase will not be too high, but at the same time as the price increase, the quality promise and service value that the goods can provide to consumers are expected to increase simultaneous.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
